Form 4 for YDES YD Bio Ltd
Accepted 2026-09-08 16:00:16 ET · period of report 2026-09-04 · accession 0001213900-26-098030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 16:00 | 2026-09-04 | YDES | Shen Ethan PhD | CEO, Dir | P - Purchase | $3.67 | +18.4K | 11.24M | +0.2% | +$67.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-04 | P | A | 18,378 | $3.67 | 11,242,531 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above. |